Article Sidebar

PDF (Tiếng Việt)
Published: 2026-01-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v198i1.4566
Issue
Vol. 198 No. 1 (2026)
Section
Các bài báo
How to Cite
Mạnh, T. H., Trường, Đỗ G., Long, N. V., Thuận, L. M., Đức, L. M., Thành, D. V., Giang, P. T., & Hà, V. T. (2026). Preliminary assessment of the clinical efficacy of intra-articular umbilical cord-derived mesenchymal stem cell therapy combined with autologous platelet-rich plasma in the treatment of primary knee osteoarthritis at Buu Dien Hospital. Journal of Medical Research, 198(1), 460-470. https://doi.org/10.52852/tcncyh.v198i1.4566

Preliminary assessment of the clinical efficacy of intra-articular umbilical cord-derived mesenchymal stem cell therapy combined with autologous platelet-rich plasma in the treatment of primary knee osteoarthritis at Buu Dien Hospital

Tran Hung Manh, Do Gia Truong, Nguyen Van Long, Le Minh Thuan, Le Manh Duc, Duong Van Thanh, Pham Truong Giang, Vu Thi Ha

Main Article Content

Abstract

The study was conducted to evaluate the clinical outcomes of intra-articular injection of allogeneic umbilical cord-derived mesenchymal stem cells combined with autologous platelet-rich plasma in patients with knee osteoarthritis. This was a prospective, interventional, longitudinal study which was performed on 20 patients diagnosed with knee osteoarthritis (40 knees) according to the 1991 American College of Rheumatology (ACR) diagnostic criteria and classified as grade 2 - 3 based on the Kellgren-Lawrence system, at Buu Dien Hospital. The results showed that after 6 months of treatment, all monitored pain symptoms improved significantly (p < 0.001). After 3 months, the proportion of patients with joint stiffness decreased to 15%, and by 9 months this rate further declined to 12.5%. The reduction in joint stiffness was statistically significant (p < 0.001). The VAS score decreased significantly from 5.95 ± 0.82 before treatment to 0.1 ± 0.44; the WOMAC score decreased significantly from 55.9 ± 8.4 before treatment to 5.65 ± 2.6 after 9 months (p < 0.001). The combination of umbilical cord-derived mesenchymal stem cell therapy with autologous platelet-rich plasma in the treatment of knee osteoarthritis provided marked improvement in clinical symptoms.

Article Details

Keywords

Umbilical cord mesenchymal stem cells, knee osteoarthritis, stem cell treatment

References

1. Felson DT. Osteoarthritis as a disease of mechanics. Osteoarthritis Cartilage. 2013; 21(1): 10-15. doi:10.1016/j.joca.2012.09.012.
2. Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013; 21(9): 1145-1153. doi:10.1016/j.joca.2013.03.018.
3. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol. 2013; 9(10): 584-594. doi:10.1038/nrrheum.2013.109.
4. Filardo G, Kon E, Di Martino A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord. 2012;13:229. Published 2012 Nov 23. doi:10.1186/1471-2474-13-229.
5. Zeng W, Wang G, Liao X, Pei C. Efficacy of Intra-Articular Injection of Platelet-Rich Plasma Combined with Mesenchymal Stem Cells in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Int J Clin Pract. 2022; 2022: 2192474. doi:10.1155/2022/2192474.
6. Zhao J, Liang G, Han Y, et al. Combination of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) in the treatment of knee osteoarthritis: a meta-analysis of randomised controlled trials. BMJ Open. 2022; 12(11): e061008. Published 2022 Nov 16. doi:10.1136/bmjopen-2022-061008.
7. Matas J, Orrego M, Amenabar D, et al. Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. Stem Cells Transl Med. 2019; 8(3): 215-224. doi:10.1002/sctm.18-0053.
8. Samara O, Jafar H, Hamdan M, et al. Ultrasound-guided intra-articular injection of expanded umbilical cord mesenchymal stem cells in knee osteoarthritis: a safety/efficacy study with MRI data. Regen Med. 2022; 17(5): 299-312. doi:10.2217/rme-2021-0121.
9. Lamo-Espinosa JM, Mora G, Blanco JF, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2016; 14(1): 246. Published 2016 Aug 26. doi:10.1186/s12967-016-0998-2.
10. Weiss J.N. Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis. In: Orthopedic Stem Cell Surgery. Springer, Cham. 2021. DOI: 10.1007/978-3-030-73299-8_30.
11. Dhillon J, Kraeutler MJ, Belk JW, Scillia AJ. Umbilical Cord-Derived Stem Cells for the Treatment of Knee Osteoarthritis: A Systematic Review. Orthop J Sports Med. 2022; 10(7): 23259671221104409. doi:10.1177/23259671221104409.